Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14788883 | 0.86 | HDAC6 (0.32) | CA14CA12CA1CA2HDAC1 | |
| SCHEMBL14788868 | 0.86 | HDAC6 (0.32) | CA14CA12CA1CA2HDAC1 | |
| SCHEMBL14125029 | 0.80 | CA14 (0.42) | CA14CA12CA1CA2HDAC1 | |
| SCHEMBL16079462 | 0.77 | HDAC6 (0.35) | CA14CA12CA1CA2HDAC1 | |
| SCHEMBL14788871 | 0.77 | L3MBTL1 (0.38) | CA14CA12CA1CA2HDAC1 | |
| SCHEMBL14788878 | 0.77 | L3MBTL1 (0.38) | CA14CA12CA1CA2HDAC1 | |
| SCHEMBL3049672 | 0.74 | CA14 (0.41) | CA14CA12CA1CA2HDAC1 | |
| SCHEMBL14777934 | 0.74 | HDAC6 (0.32) | CA14CA12CA1CA2HDAC1 | |
| SCHEMBL14788872 | 0.72 | HDAC6 (0.35) | CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL14125030 | 0.72 | HDAC6 (0.35) | CA14HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8784774-B2 | Labeled molecular imaging agents and methods of use | GENERAL ELECTRIC COMPANY (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130071332-A1 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE | GENERAL ELECTRIC COMPANY (US) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071332-A1 | LABELED MOLECULAR IMAGING AGENTS AND METHODS OF USE | SLC7A11, GLS, SLC3A2 | CA14 579/4885CA12 416/4885CA1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.